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Objective: The study evaluated the utility of transplanting bone marrow stromal
cells in a porcine myocardial infarction model.
Methods: A myocardial infarction was created by occluding the distal left anterior
descending artery in pigs with coils and Gelfoam sponge. Sternal bone marrow was
aspirated, and stromal cells were cultured and induced to differentiate to a myogenic
phenotype with 5-azacytidine. Four weeks after coronary artery occlusion, sestamibi
technetium single-photon emission computed tomographic scans were performed,
and then either a graft of 100  106 bone marrow stromal cells (n  5, 30% labeled
with bromodeoxyuridine) or culture medium (n  6) was injected into the infarct
region. Four weeks later the tomographic scans were repeated and cardiac function
was assessed with pressure and volume measurements. Morphologic and histologic
characteristics of the heart were also studied.
Results: Histologic examination found bromodeoxyuridine-labeled cells within the
infarct region in islands that had sarcomeres and Z-bands and stained positively for
cardiac specific troponin I. The bone marrow stromal cell transplant sites had a
greater (P .05) capillary density than did the control sites. The tomographic scans
showed that the hearts with the cell transplants had increases in stroke volume,
regional perfusion, and wall motion (P  .05 for all groups) relative to the control
hearts. The pressure-volume analysis showed improvement (P  .05) in end-
systolic elastance and preload recruitable stroke work in the transplantation group
relative to the control group. The left ventricular chamber size was smaller (P .05)
and the scar thickness was greater (P .05) in the hearts with transplanted cells than
in the control hearts (P  .06).
Conclusion: 5-Azacytidine-treated bone marrow stromal cells transplanted into the
myocardial infarct region formed islands of cardiac-like tissue, induced angiogen-
esis, prevented thinning and dilatation of the infarct region, and improved regional
and global contractile function.
After a myocardial infarction some heart cells are lost and othershibernate because they are underperfused. Cell transplantationoffers the promise to replace the lost cells (myogenesis) andperfuse the hibernating cells (angiogenesis). Myogenic cells mayprovide elasticity that stabilizes the infarct region and preventsinfarct thinning, chamber dilatation, and congestive heart failure.
Angiogenesis may be accomplished by inducing blood vessel ingrowth and by
participation of the transplanted cells in the new vasculature.
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Adult bone marrow contains stromal cells, which can
differentiate into myogenic1 and endothelial2 progenitor
cells. These stromal cells should be ideal to induce both
myogenesis and angiogenesis when transplanted after a
myocardial infarction. It has been reported that marrow
stromal cells implanted into an infarct region differentiated
to a fibroblast phenotype, whereas stromal cells implanted
into normal myocardium differentiated toward a cardiomy-
ocyte appearance.3,4 In a previous study we found that both
fresh and cultured bone marrow stromal cells induced an-
giogenesis when transplanted into a cryoinjured region in
rats.5 However, only stromal cells treated before transplan-
tation with 5-azacytidine to induce a myogenic phenotype
contributed to myogenesis and improved heart function by
preventing scar thinning and chamber dilatation. We there-
fore transplanted adult bone marrow stromal cells that had
been treated with 5-azacytidine into infarcted myocardium
in a porcine model to investigate the survival of the trans-
planted stromal cells in the myocardial infarct region, the
differentiation of these cells into heart cells and blood vessel
cells, and the effects of the implanted cells on regional
perfusion, wall motion, and global heart function. We found
that the transplanted stromal cells survived and formed new
cardiac tissue and capillaries. Myocardial regional perfusion
was improved and contractile function was preserved after
transplantation.
Methods
Animal Preparation
Yorkshire pigs (35 kg; Charles River Canada, Quebec City, Que-
bec, Canada) were used. All procedures were approved by the
Animal Care Committee of The Toronto General Hospital and
were performed in accordance with the “Guide for the Care and
Use of Laboratory Animals” prepared by the Institute of Labora-
tory Animal Resources, National Research Council, and published
by the National Academy Press, revised 1996.
The animals were medicated in advance with ketamine hydro-
chloride (20 mg/kg intramuscularly). Anesthesia was induced with
a ventilation mask with 4% to 5% isoflurane and oxygen at 2 to 3
L/min. The animals were intubated with a cuffed endotracheal tube
and ventilated with 100% oxygen to maintain PaCO2 between 35
and 45 mm Hg. Anesthesia was maintained with 1% to 2.5%
isoflurane in oxygen at a flow rate of 2 to 3 L/min and inspired
oxygen fraction of 100%. Electrocardiography was used to mon-
itor heart rate, rhythm, and ST-segment changes during the surgi-
cal procedure.
Cell Isolation and Preparation
With the animal under general anesthesia, 10 mL sternal bone
marrow was aspirated with a bone marrow aspirate needle and then
cultured in cell culture medium (Iscove modified Dulbecco me-
dium with 20% fetal bovine serum, 100-U/mL penicillin G, 100-
g/mL streptomycin, and 0.2-g/mL amphotericin B). The cells
were incubated with 95% air and 5% carbon dioxide at 37°C.
5-Azacytidine induction of stromal cells to a myogenic phe-
notype. Forty-eight hours after the initiation of the culture, 5-aza-
cytidine was added into the culture medium at a final concentration
of 10 mmol/L. The medium was changed 24 hours later, and the
cells were continually cultured for 4 weeks with medium changed
every 2 to 3 days. Because hematopoietic stem cells do not attach
onto the culture dish, they were removed with the culture medium
changes. The cells were subcultured to 60% confluency. The cells
were similarly incubated with 5-azacytidine 1 day before trans-
plantation.
Cell labeling with bromodeoxyuridine. To discriminate the
transplanted cells in the recipient myocardium, 30% of the trans-
planted cells were labeled with bromodeoxyuridine (BrdU) as
previously described elsewhere.6 Briefly, 74 L of a 0.4% BrdU
solution was added into each culture dish with 30 mL of culture
medium 2 days before transplantation and incubated with the cells
for 24 hours.
Cell preparation for transplantation. The stromal cells were
dissociated from the culture dish with 0.05% trypsin in phosphate-
buffered saline solution (PBS), collected, and centrifuged at 570g.
The cells were suspended with culture medium to obtain a con-
centration of 100  106 cells in 1.5 mL. The cell suspension was
aspirated into two tuberculin syringes.
Immunohistochemical Staining
Cultured bone marrow stromal cells were washed with PBS and
fixed with methanol at -20°C for 20 minutes. After being washed
with PBS three times, the cells were incubated with the monoclo-
nal antibodies against cardiac-specific troponin I (Spectral Diag-
nostics Inc, Toronto, Ontario, Canada), CD34 (Vector Laborato-
ries Inc, Toronto, Ontario, Canada), desmin (DAKO Diagnostics
Canada, Inc, Toronto, Ontario, Canada), -smooth muscle actin
(Sigma Aldrich, Toronto, Ontario, Canada), and vimentin (Amer-
ican Research Products, Toronto, Ontario, Canada) at 37°C for 45
minutes. The cells in the control group were incubated with PBS
without antibodies. After incubation the cells were washed three
times (15 minutes each) with PBS and then incubated with sec-
ondary antibodies conjugated with peroxidase at 37°C for 45
minutes. The samples were washed three times with PBS and then
immersed in diaminobenzidine and hydrogen peroxide solution
(2-mg/mL diaminobenzidine and 0.03% hydrogen peroxide in 0.02
mL/L phosphate buffer) solution for 15 minutes. The samples were
coverslipped and photographed.
The positively and negatively staining cells in two dishes for
each transplant were counted at 200 times magnification. Five
high-power fields in each culture dish were randomly selected and
the positively and negatively staining cells in each field were
counted and averaged. The results were expressed as percentage of
positive cells.
Myocardial Infarction
With the animal under general anesthesia the right carotid artery
was exposed and a coil (10  1 mm; Target; Boston Scientific
Corp, Natick, Mass) was lodged in the distal third of the left
anterior descending coronary artery and in the origin of the second
diagonal artery with a catheter.6 A piece of Gelfoam sponge (1 
1  10 mm; Upjohn Company of Canada, Dons Mills, Ontario,
Canada) was placed into each coil to ensure complete occlusion of
the arteries. The surgical incision was closed. Blood pressure, heart
rate, and electrocardiographic data were monitored during the
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procedure and for 3 hours afterward. Severe ventricular arrhyth-
mias appearing during this time were treated by intravenous ad-
ministration of lidocaine. Numorphan (5.0 mg every hour for 6
hours after operation) was administered intramuscularly for pain
control. Antibiotics were given as necessary.
Autologous Cell Transplantation
With the animal under general anesthesia the infarct region was
exposed through a left thoracotomy 4 weeks after the myocardial
infarction.6 The animals were randomly assigned into transplant
and control groups. In the transplant group the cell suspension,
described in the section on cell preparation for transplantation, was
injected though a 27-gauge needle into the myocardial infarct
region (n  5). One syringe containing 0.75 mL was injected into
the center of the infarct region, and another syringe with the
remaining 0.75 mL was injected into 4 regions in the periphery of
the infarct region. Each injection site was closed with a purse-
string suture. Culture medium (1.5 mL) was injected into the scar
of the control hearts (n  6) according to the same procedure used
in the cell transplant group. The pericardium was closed with 4-0
Prolene sutures (Ethicon, Inc, Somerville, NJ). The ribs were
approximated with No. 22 sternal wires, and the chest was closed
in three layers. An intercostal block with 3 mL 0.25% bupivacaine
(Marcaine E) was administered locally for extended postoperative
analgesia. Analgesics and antibiotics were administered as men-
tioned previously.
Sestamibi (2-Methoxy-2-Methylpropyl Isonitrile)
Technetium (Tc 99m) Single-Photon Emission
Tomography
Global and regional perfusion and function of normal pigs were
assessed by sestamibi technetium single-photon emission tomo-
graphic scans (MIBI) as previously described.6 At 4 weeks after
myocardial infarction but before transplantation a MIBI scan was
performed on all the animals. The animals were then randomly
separated into control and transplantation groups. Four weeks after
cell transplantation the heart function of all the animals was
evaluated again by MIBI scan. Each animal was sedated with
ketamine at 20 mg/kg, electrocardiographic leads were applied,
and 20 mCi of sestamibi technetium (E.I. du Pont de Nemours and
Company, Wilmington, Del) was administered intravenously. Re-
gional and global reconstructions of the heart were performed with
AutoSpect software and quantified by Cedars-Sinai Quantitative
Gated Spect software. Regional perfusion, wall motion and wall
thickening, and global function were evaluated as described in a
previous publication.6
Cardiac Function Measurements
The heart function was evaluated with Millar micromanometer
pressure and conductance volume catheters (Millar Instruments,
Inc, Houston, Tex) 4 weeks after cell transplantation.6 With the
animal under general anesthesia, a midline sternotomy was per-
formed to expose the heart. Calibrated pressure and volume cath-
eters were inserted into the left ventricle through the apex. The
pressure and volume data were collected with the Conduct-PC
software (CardioDynamics, Zoetermeer, The Netherlands). Three
baseline values were obtained. At least 3 values were recorded
after clamping of the superior and inferior venae cavae until the
left ventricle had emptied, as indicated on the volume tracing.
Parallel conductance was evaluated after the injection of hyper-
tonic saline solution into the pulmonary artery, and the volume
measurements were corrected for the parallel conductance. The
volume measurements were normalized for body weight. Pressure-
volume loops before and after vena cava occlusion were plotted.
The area within each curve was plotted against the end-diastolic
volume to evaluate the preload recruitable stroke work as previ-
ously described elsewhere.6
Heart Morphologic Measurements
Ventricular volume. After the function measurements the
heart was relaxed by perfusing it with 20-mmol/L potassium
chloride in saline solution and then excised. The left ventricular
chamber volume was measured by the technique of Pfeffer and
Braunwald.7 A balloon was inserted into left ventricle. The balloon
was increased in size by the addition of saline solution until the
ventricular pressure reached 30 mm Hg. The injected saline solu-
tion volume was recorded as passive ventricular volume.
Planimetry. The size of the infarct region of the heart was
measured.8 After the passive volume measurement was completed,
the heart was fixed in distention (30 mm Hg) with an intraventric-
ular balloon with 10% phosphate-buffered formalin solution for 2
weeks. The heart was cut into 5-mm thick sections. Heart sections
were photographed and the scar area was quantified with comput-
erized planimetry (Jandal Scientific Sigma-Scan, Corte Madera,
Calif).
Histologic Studies
Tissue samples (0.5 cm3) from the transplant and control sites were
collected from the fixed heart after the heart morphologic study.
The tissues were embedded in paraffin and cut into 10-m thick
sections. The sections were serially rehydrated with 100%, 95%,
and 70% ethanol after deparaffinization with toluene. The sections
were stained with hematoxylin and eosin for cell and blood vessel
identification. The sections were also immunohistochemically
stained for BrdU and troponin I.
Angiogenesis. Blood vessels in hematoxylin and eosin-
stained tissue samples obtained from three locations within the
infarct region of each pig were identified. The vascular density in
each tissue section was counted at 400 magnification by an ob-
server blinded to the treatment group. Five high-power fields in
each section were randomly selected and their vascular densities,
expressed as blood vessels/0.2 mm2, were averaged. Averages of
5 fields and 3 samples from each animal were used for comparison.
Immunohistochemical staining. Endogenous peroxidase in
the sample was blocked with 3% hydrogen peroxide for 10 min-
utes at room temperature. The sample was treated with pepsin for
5 minutes at 42°C and with 2N hydrochloric acid for 30 minutes at
room temperature. After being rinsed with PBS three times, the
samples were incubated with monoclonal antibodies against BrdU
or PBS (negative control) in a moist chamber for 16 hours at room
temperature. The slides were rinsed with PBS, incubated with
secondary antibody, immersed in diaminobenzidine and hydrogen
peroxide solution, and photographed as described in the section on
immunohistochemical staining.
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Data Analysis
All data were expressed as mean  SE. The perfusion and wall
motion measurements and the left ventricular volumes and ejection
fractions obtained from the MIBI scans were subjected to 2-way
analysis of variance. Left ventricular pressure and volume data
were subjected to an analysis of covariance, evaluating group,
time, and interactive group and time effects across the range of
ventricular volumes. Other variables were assessed by 2-way anal-
ysis of variance or, when appropriate, by the t test.
Results
Bone Marrow Stromal Cell Culture
The bone marrow cells that attached to the bottom of the
culture dish within 2 to 3 days proliferated in culture. The
medium was changed every 2 days, and hematopoietic stem
cells that did not attach to the dish were washed from the
culture with each medium change. The first 24-hour expo-
sure of the cultured stromal cells to 5-azacytidine, which
occurred 2 days after the initiation of culture, did not cause
any obvious morphologic changes. The cells grew rapidly
for 4 weeks and were passaged when they had reached 60%
confluence. The final exposure to 5-azacytidine 1 day before
transplantation did not produce any morphologic changes in
the cultured cells. When the cells were permitted to prolif-
erate to confluence, they formed myotubules (Figure 1).
Before transplantation the cells were identified with anti-
bodies. One hundred percent of the cultured cells stained
positively for vimentin, and 80%  6% of the cells stained
positively for -smooth muscle actin. Desmin was observed
in 30%  8% of the cultured cells (Figure 1). None of the
cells stained positively for bone, cartilage, CD34, or tropo-
nin I. The in vitro BrdU labeling efficiency of the stromal
cells was 80%  10%.
Histologic Characteristics
Fibrous tissue and some islands of myocardium were ob-
served in the infarct region of the media-injected control
group. More cardiac islands were observed in the cell trans-
planted infarct region than in the control region (Figure 2,
c). Many of the cells in the islands stained positively for
BrdU (Figure 2, a). No BrdU-labeled cells were found in the
host myocardium or in the control hearts. Some of the
BrdU-labeled cells in the transplant area contained orga-
nized sarcomeres and Z-bands and stained positively for
cardiac-specific troponin I, whereas other BrdU-stained
cells appeared to become interstitial cells (fibroblasts; Fig-
ure 2, b). Gap junctions were present between the BrdU-
labeled cells. No junctions were seen between the BrdU-
labeled cells and the host cardiomyocytes. The capillary
density in the transplanted infarct region (9.2  1.1 blood
vessels/0.2 mm2) was greater (P  .05) than that in the
control infarct region (3.4  0.4 blood vessels/0.2 mm2).
Some endothelial cells in the blood vessels in the transplant
sites stained positively for BrdU (Figure 3).
Heart Function
MIBI scan. Before myocardial infarction the ejection
fraction was 50%  5% and the left ventricular end-dia-
stolic volume was 41 6 mL (n 8). The myocardium had
normal perfusion and wall motion. At 4 weeks after myo-
cardial infarction the ejection fraction was 43%  4% (n 
11) and the left ventricular end-diastolic volume was 68 
5 mL (n  11). There was limited perfusion to the infarct
region. The animals were randomly assigned to the cell (n
5) or the media (n  6) transplantation group. At 4 weeks
after transplantation heart rate did not differ between groups
and had not changed with transplantation. No arrhythmias
were detected during electrocardiographic monitoring. The
Figure 1. Appearance of 4-week-old 5-azacytidine-treated bone
marrow stromal cells in culture immediately before transplanta-
tion (original magnification 400). Staining was positive for vi-
mentin (stromal cell marker, b), -smooth muscle actin (c), and
desmin (myogenic progenitor marker, d) in 100%, 80%  6%, and
30%  8% of cells, respectively. Large arrows indicate positively
stained cells and small arrows indicate the negatively stained
cells). When the induced stromal cell culture became confluent,
myocyte was present (a, arrow).
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MIBI scan data were expressed as the difference of each
parameter between the pretransplantation and 4-week post-
transplantation value for each animal. At 4 weeks the re-
gional perfusion of the infarct region had increased (P 
.05) in the transplant group but not in the medium-injected
control group (Figure 4, a). Regional wall motion had also
improved (P  .05) in the transplant group relative to the
control group (Figure 4, b). Cell transplantation increased
wall thickening significantly (P  .05) relative to the con-
trol group (Figure 4, c). The hearts with transplanted cells
had better global function than did the control hearts (Figure
5). Stroke volumes were increased (P  .05) in the trans-
plant group but not in the control group (Figure 6, a). The
increased stroke volumes were achieved at lower end-dia-
stolic volumes (P .05 by analysis of covariance). Ejection
fraction was increased in the transplant group and decreased
in the control group, but the difference was not statistically
different (Figure 6, b).
Figure 2. Tissue slices obtained 4 weeks after implantation from
transplanted area stained for BrdU (a) and troponin I (b). Islands
of cardiac tissue in scar area of transplanted hearts stained
positively for both BrdU and troponin I (original magnification
400). a, Islands contained BrdU-stained differentiated cardio-
myocytes (small arrows) with organized sarcomeres and Z-bands;
some transplanted cells (BrdU-positive cells) also differentiated
into interstitial cells in fibrotic tissue (open arrows; original
magnification 400). b, Large arrows point to intercalated discs
(original magnification 400). c, Hematoxylin and eosin-stained
tissue showing transplanted muscle (m; original magnification
40).
Figure 3. Immunohistochemical staining for BrdU of myocardial
scar tissue 4 weeks after cell transplantation (original magnifi-
cation 100). Some endothelial cells in blood vessels in trans-
planted region stained positively for BrdU (arrow).
Figure 4. Changes in resting regional perfusion (a), wall motion
(b), and wall thickness (c) of myocardial infarct region in trans-
plant (n  5) and control (n  6) groups from before transplan-
tation to 4 weeks after transplantation, as measured by the MIBI
scan. Regional perfusion in transplant group was maintained,
whereas that in control groups decreased (P < .05). Regional
wall motion and wall thickness were increased (P < .05) in
transplant group. Bar heights represent mean; error bars repre-
sent SE.
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Preload-recruitable stroke work. Four weeks after cell
transplantation, intraventricular pressure and volume were
measured at rest and during vena cava occlusion, and pres-
sure-volume loops were constructed. The area within each
loop was calculated as the stroke work. Greater stroke work
was found in the transplant group than in the media-injected
control group at similar end-diastolic volumes (Figure 7)
(P  .01 by analysis of covariance). In addition, the slope
of the relationship was greater (P  .05) in the transplant
group than in the control group.
Morphologic Study
The left ventricular chamber volumes of the hearts arrested
at 30 mm Hg pressure were smaller (P  .05) in the
transplanted group (64.3  10.5 mL) than in the medium-
injected control group (91.7  5.9 mL). The scar thickness
was greater (P  .05) in the transplant group (6.9  0.7
mm) than the control group (3.9  0.4 mm). The size of the
infarct region tended to be smaller in the transplant group
than in the control group, but the difference was not statis-
tically significant (P  .06).
Discussion
Myocardial transplants of cultured heart cells,6 skeletal
myoblasts,9 smooth muscle cells,10 and bone marrow cells5
have been demonstrated to prevent heart failure after a
myocardial injury. The advantages of bone marrow stromal
cells include the clinical ease of obtaining a bone marrow
aspirate and the possibility of differentiating the stromal
cells into cardiomyocytes that may form gap junctions and
beat synchronously with the host myocardium (myogen-
esis).1 In addition, the stromal cells may differentiate into
endothelial progenitor cells that may participate in neovas-
cularization after transplantation (angiogenesis).2
Shake and colleagues4 purified myogenic cells from the
bone marrow and transplanted these myogenic cells into the
infarcted myocardium of porcine hearts. The cells survived
in the transplanted area, formed a muscle tissue, reduced
wall thinning by 26%, and attenuated regional contractile
Figure 5. Representative 3-dimensional views of reconstructed
hearts from gated MIBI scan. Animals in control (a) and trans-
plant (b) groups were scanned at 4 weeks after cell transplan-
tation. a, In control group, end-diastolic volume was 82 mL,
end-systolic volume was 52 mL, and ejection fraction was 37%. b,
In transplant group, end-diastolic volume was 72 mL, end-systolic
volume was 40 mL, and ejection fraction was 50%. Figure 6. Differences in stroke volumes (a) and ejection fractions
(b) from before transplantation to 4 weeks after transplantation,
as measured by MIBI scan, in transplant (n  5) and control (n 
6) groups. Stroke volume in transplant group was greater (P <
.05) than in control group. Although difference in ejection fraction
appeared increased relative to that in control hearts, differences
did not differ statistically significantly between groups (NS). Bar
heights represent mean; error bars represent SE.
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dysfunction relative to the control media-injected hearts.
Orlic and associates11 transplanted cultured bone marrow
stem cells into viable ventricular myocardium adjacent to a
recent infarct in a murine myocardial infarct model. The
transplanted cells formed myocardium that occupied part of
the infarct zone. The newly formed myocardium consisted
of proliferating cardiomyocytes, endothelial cells, and
smooth muscle cells derived from stem cells. Myocardial
function of the hearts with cell transplants was significantly
better than that of the control hearts. We previously used
5-azacytidine to induce cultured rat bone marrow stromal
cells to become myogenic cells in vitro.5 The cultured
5-azacytidine-treated stromal cells formed more myotubes
at confluence than did the untreated stromal cells at conflu-
ence. Both the chemically induced and the untreated bone
marrow stromal cells were implanted into transmural myo-
cardial scars produced by cryoinjury in a rat model. Only
the hearts with the 5-azacytidine-treated stromal cell trans-
plants had improved cardiac function relative to control
hearts that received culture medium alone. Neither fresh
bone marrow nor cultured but untreated cells improved
function. We attributed the effectiveness of 5-azacytidine
treatment in improving myocardial function to an increased
conversion in culture of stromal cells to myogenic progen-
itor cells,12 because only muscle cell transplantation has
been demonstrated to preserve ventricular function.6,9,10,13
Conversion of bone marrow stromal cells to a myogenic
phenotype was important in inducing myogenesis in myo-
cardial scar tissue. 5-Azacytidine methylated DNA is
thought to alter gene expression.14 The combination of
5-azacytidine and the myogenic determination gene myoD
was found to be more effective in increasing the frequency
of myogenic conversion than was chemical induction
alone.15 The host cardiac milieu may also contribute to the
conversion of stromal cells to cardiomyocytes after cell
transplantation.3 Alternate approaches include electrical
stimulation, pressure, and stretch which also may induce
myogenic differentiation of stromal cells and promote cell-
to-cell integration and modification of the extracellular ma-
trix.16
Immediately before transplantation most of the 5-azacy-
tidine-treated stromal cells had assumed a myogenic phe-
notype, with 80% staining positively for -smooth muscle
actin and 30% staining positively for desmin.17,18 Four
weeks after implantation the transplanted cells had formed
islands of cardiac tissue in the myocardial infarct region,
and many of the cells stained positively for BrdU (labeled
before transplantation, Figure 2). The BrdU-stained cardio-
myocytes contained organized sarcomeres and Z-bands and
stained positively for cardiac-specific troponin I. Most of
the well-defined islands of BrdU-stained cardiac tissue were
located in the periphery of the infarct region, near the
preserved host myocardium. Many of the transplanted por-
cine stromal cells formed junctions between the cells that
were more distinct than those we found when rat stromal
cells were implanted into the center of a homogeneous
scar.5 The better-differentiated cell-to-cell connections
could represent a species difference but more likely reflect
the transplantation of porcine stromal cells closer to func-
tioning myocardium. The implanted rat cells in the scar may
have been too distant from the viable recipient cardiomyo-
cytes to be influenced by the milieu of the host myocardium.
Similar to the findings of Orlic and associates11 with a
murine model, we showed that transplanted porcine stromal
cells formed cardiomyocytes and endothelial cells in the
infarct region.
Within the islands of BrdU-labeled cardiac tissue were
capillaries lined with some BrdU-labeled endothelial cells
(Figure 3). Kobayashi and coworkers19 also found that bone
marrow cell implantation induced angiogenesis in a rat left
anterior descending coronary artery ligation model. Asahara
and colleagues2 demonstrated that circulating bone marrow
endothelial progenitor cells entered the infarct region after
left anterior descending coronary artery ligation in the
mouse and were associated with sprouting blood vessels in
the border of the infarct, perhaps contributing to the neo-
vascularization of the infarct region. The treatment of an
infarcted region with vascular endothelial growth factor
mobilized endothelial progenitor cells from the bone mar-
row for blood vessel formation. This can be accomplished
more efficiently by direct transplantation of bone marrow
cells into the infarct region. In our study the transplanted
stromal cells contributed about 10% of the endothelial cells
of newly formed blood vessels according to the percentage
Figure 7. Heart function was measured with Millar and conduc-
tance catheters (measuring pressure and volume) at 4 weeks
after cell transplantation, and left ventricular stroke work and
end-diastolic volume relations are shown. Slope of preload-
recruitable stroke work in transplant group (diamonds) was
greater (P < .05) than that in control group (circles). Data points
represent mean; error bars represent SE.
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of BrdU-labeled cells lining the capillaries. Because stromal
cells are known to secrete vascular endothelial growth fac-
tor,20 the transplanted stromal cells also accelerated neovas-
cularization other than by direct involvement in blood ves-
sel formation.
The improvement in cardiac function of the heats with
stromal cell transplants relative to the control hearts resulted
from the preservation of left ventricular volume. In the
control hearts the infarct region thinned and dilated as a
result of remodeling of the infarct scar, with a resultant
deterioration in ventricular function. This phenomenon can
be explained by the Laplace Law ( Pr/w, where  is wall
stress, P is transmural pressure, r is the radius of the
ventricular chamber, and w is wall thickness). The trans-
planted cells maintained the thickness and probably the
elasticity of the scar, stabilizing the infarct region, prevent-
ing left ventricular chamber dilatation, and thus avoiding
the increased left ventricular wall stress seen in the control
hearts. Transplants of heart cells,6 skeletal muscle cells,9
and smooth muscle cells10 have prevented scar thinning and
chamber dilatation and improved heart function. This has
not proved the case with a nonmuscle cells, such as endo-
thelial cells.13
The cell transplantation also improved regional function.
Both regional thickening and wall motion were better in the
transplant group than in the control group. Similar results
have been reported in experimental21 and clinical22 skeletal
myoblast transplantation. The mechanism responsible for
the improved regional contractility has not been determined.
The transplanted stromal cell–derived cardiomyocytes may
have been beating, and those implanted near to the host
myocardium may have been beating synchronously with the
heart. However, neither heart cells nor bone marrow stromal
cells have been shown to beat synchronously with the host
heart, although both communicate with each other by gap
junctions. Neither skeletal muscle myoblasts nor smooth
muscle cells beat synchronously, and yet both have contrib-
uted to improved regional and global function. A more
likely explanation is that the improvement in regional func-
tion resulted from angiogenesis induced by the stromal cell
engraftment. Increased perfusion could have started hiber-
nating host cardiomyocytes, particularly those in the border
zone, beating synchronously with the heart. Regional con-
traction may have been improved by the tethering effect of
the adjacent myocardium.23 Increasing the elasticity of the
infarct region would contribute to improved regional func-
tion from adjacent regions. The improvement in regional
function probably resulted from a combination of factors,
including myogenesis and angiogenesis.
This study has important limitations. The small number
of animals limited the detection of smaller differences be-
tween groups. The pigs in this study were young and grow-
ing, and their bone marrow may have contained more car-
diomyocyte progenitor cells than would be found in older
animals. Primary cell cultures from young animals grow
more rapidly than do cells obtained from older animals. For
stromal cells transplants to be successful in adults, sufficient
numbers of cardiomyocyte progenitor cells must be ob-
tained, and their rate of cell division must be rapid enough
to provide the number of cells required to repopulate an
infarct. Although we found stromal cell-derived cardiomy-
ocytes in the transplant region that were connected with
each other, we did not demonstrate that these cells commu-
nicated with the host myocardium. We could not determine
whether the transplanted cells were beating. Future studies
are needed to determine the dose-dependent effects of im-
planted stromal cells on heart function and arrhythmias for
at least 1 year.
In summary, chemically induced porcine bone marrow
stromal cells obtained from young animals was successfully
transplanted into myocardial scar tissue caused by a coro-
nary artery occlusion. The transplanted cells formed capil-
laries and islands of cardiac tissue that contained differen-
tiated cardiomyocytes, and the transplantation improved
ventricular function relative to that of control hearts.
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